BIOCORP announces the CE marking of SoloSmart ® , an accessory medical device for SANOFI Solostar ® pens at the occasion of EASD
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of SoloSmart® today, on the opening of the EASD (European Association for the Study of Diabetes) annual meeting in Stockholm, Sweden. SoloSmart® is fully compatible with the pharmaceutical group's SoloStar® injection pens.
The result of the collaboration initiated in 2019 between the two companies is presented as an accessory to the Sanofi SoloStar®/ DoubleStar® insulin pens, which records information about the insulin dose, time and date of each injection and transmits it via Bluetooth to a compatible mobile application. The SoloSmart® device automatically and accurately records injected doses, eliminating the need for manual logbooks and possibly allows for adapting to new patient uses of continuous glucose monitoring systems or connected BGM.
Developed by BIOCORP's R&D department, SoloSmart® meets the latest requirements of the new European medical device regulation. Its commercial launch will begin early 2023 in the distribution networks approved by SANOFI and its partners. This partnership strategic step validates a substantial milestone - more details will be given on September 29th (half year results).
Eric Dessertenne, CEO of BIOCORP, said: "The expertise we have developed with Mallya leads us to improve and develop a new device by miniaturizing it, keeping data reliability. We are today very proud of developments achieved by our respective R&D and to present them today at the EASD, which brings together an international diabetes community. The strength of this industrial and commercial partnership has resulted in a technological achievement which will allow people living with diabetes, users of SoloStar® pens, to benefit from a solution that improves their daily life thanks to a presentation that is very compact but still secure and accurate.”
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220918005029/en/
Contact information
CONTACTS BIOCORP
Jacques Gardette
Chairman of the Board
Éric Dessertenne
Chief Executive Officer
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
CONTACTS ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 47 26
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results2.5.2024 13:05:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced results for the fiscal first quarter ended March 31, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502994935/en/ Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results (Graphic: Business Wire) Select First Quarter 2024 Financial Highlights Revenue was $106.7 million for the 2024 first quarter, an increase of 1.2% compared to $105.5 million for the same period last year. U.S. revenue was $53.8 million for the 2024 first quarter, an increase of 0.7% compared to $53.4 million for the same period last year. International revenue was $52.9 million for the 2024 first quarter, an increase of 1.6% compared to $52.1 million for the same period last year. Annuali
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer2.5.2024 13:00:00 CEST | Press release
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis. Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer. “Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we of
Lifezone Metals to Provide its Q1 2024 Operational Update and Financial Summary on Monday, May 13, 20242.5.2024 12:30:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) will release its operational update and unaudited financial summary for the first quarter of 2024 before market open on Monday, May 13, 2024. The company invites shareholders, investors, and members of the media to join the executive team for a virtual presentation and discussion of the Q1 summary and outlook. The presentation will be followed by a Q&A session where participants can engage directly with Lifezone’s senior management. Event details: Date: Monday, May 13, 2024. Time: 10:00 AM Eastern Time. Location: Virtual (please click the webcast registration link). The presentation slides will be available on Lifezone’s website on the day of the release. The webcast will be archived and accessible for replay for a limited time after the event. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Metals (NYSE: LZM), our mission is to provide cleaner and more responsible metals productio
Florin Filote joins ThredUp as General Manager of Europe2.5.2024 12:00:00 CEST | Press release
ThredUp (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, today announced the appointment of Florin Filote as the company’s General Manager of Europe. With nearly two decades of experience in retail and ecommerce with an emphasis on building and scaling marketplace businesses, Filote will oversee the company’s European business operations, which currently span nine countries in Central and Eastern Europe. He succeeds Dan DeMeyere, who has been with ThredUp since 2010 and most recently ran the company’s international business for two years. DeMeyere is transitioning back to the U.S. business to scale technology and artificial intelligence innovation as Chief Product and Technology Officer. Filote and DeMeyere will both report to ThredUp CEO and Cofounder James Reinhart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502300242/en/ Florin Filote, General Manager of Eu
Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma2.5.2024 10:23:00 CEST | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT (SLIT-liquid) on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe. The publication is available online (https://doi.org/10.1016/j.lanepe.2024.100915) and will be available in print at a later date. This retrospective longitudinal pharmaco-epidemiological real-world study, which evaluated data over a 9-year period, included over 440,000 patients: more than 110,000 patients with allergic rhinitis, with or without asthma, treated with Stallergenes Greer SLIT-liquid and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis, with or without asthma, treated with symptomatic drugs only. The primary objective of the study was the evaluation of the real-world impact of Stallergene